Hulk Hogan, wrestling icon, dies at 71 in Florida home
CAMBRIDGE, UK - Arecor Therapeutics plc (AIM:LON:AREC) announced Monday the establishment of a new Scientific Advisory Board comprised of experts in oral drug delivery and peptide therapeutics.
The advisory board will provide technical guidance to support the company’s development of a technology platform for oral delivery of peptides with improved bioavailability compared to current approaches.
The newly appointed advisory board includes three specialists: David Brayden, Professor of Advanced Drug Delivery at University College Dublin; Randy Mrsny, Professor of Drug Delivery at the University of Bath; and Christopher Porter, Director of the Monash Institute of Pharmaceutical (TADAWUL:2070) Sciences.
"The challenge of oral peptide delivery has persisted for decades, with even the most advanced therapeutics on the market achieving less than 1% bioavailability," said Jan Jezek, Chief Scientific Officer of Arecor.
According to the company’s press release statement, the initiative aims to address patient needs in markets such as diabetes and obesity, where oral alternatives to injectable peptide drugs could potentially improve patient compliance.
Arecor noted that nearly all peptide drugs are currently available only in injectable form, and the company believes oral delivery could reduce overall healthcare burden and improve access.
The biopharmaceutical company, which focuses on advancing therapies, is leveraging its formulation and product development expertise for this initiative.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.